home / stock / fate / fate articles
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biop...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 ...